Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kaplan Fox & Kilsheimer LLPKaplan Fox is Investigating Claims Against Fulcrum Therapeutics, Inc. (FULC) on Behalf of InvestorsKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also contact...
- Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis ConferencePreviously disclosed post hoc PreciSION CF analyses of SION-719 support advancement of SION-451 + SION-2222 into the AscenSION CF Phase 2a proof-of-concept trial
- Guardant Health, Inc.Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast CancerCompanies: AstraZenecaPALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that Guardant360® CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a companion diagnostic (CDx) to identify patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from treatment with ETCAMAH™ (camizestrant), AstraZeneca’s next-generation oral selective estrogen
- Guardant Health, Inc.Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026PALO ALTO, Calif., October 08, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2026 after market close on Thursday, November 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m.
- ORGANA Highlights Simple Wellness Habits as Fall Routines ReturnSpringville, UT Thursday Oct 8, 2026 @ 3:00 PM Eastern — As summer gives way to fall and daily schedules become more structured, ORGANA is encouraging consumers to use the change of seasons as an opportunity to return to simple, consistent wellness habits. Fall often brings a shift in routines. Vacations wind down, school and work schedules settle in, temperatures cool and the busy holiday season begins to approach. For ORGANA, the transition is a reminder that wellness routines don't need to be complicated to become part of everyday life. One area that can receive less attention as temperatures fall is hydration. While people often think about water, electrolytes and minerals during hot summer months and outdoor activities, ORGANA believes attention to hydration and minerals can be part of a year-round wellness routine. "Fall is a great time to look at the little things you do every day and get back into a routine," said Larry Mills, CEO of ORGANA. "Our philosophy has always been to make wellness simple. You don't need to completely change your life when the seasons change. Consistency with a few everyday habits can go a long way." That philosophy is reflected across ORGANA's product portfolio, including its Pomegranate Mineral Drink. ORGANA Plant-Derived Trace Minerals are sourced from an ancient mineral deposit in Utah and provide a concentrated blend of naturally occurring trace minerals. The liquid format is designed to make the product easy to incorporate into an existing daily routine. ORGANA's Pomegranate Mineral Drink combines its plant-derived mineral complex with pomegranate flavor in a ready-to-use liquid format, providing another option for consumers looking to make minerals part of their everyday routine. The company's broader wellness portfolio also includes Liquid Oxygen 125 PPM and Essiac Tea, reflecting ORGANA's focus on straightforward products that can fit into different lifestyles and routines. As consumers transition into fall, ORGANA recommends focusing on habits that are realistic enough to maintain throughout the season. Drinking water regularly, paying attention to hydration even when temperatures are cooler, maintaining a consistent sleep schedule, staying active and establishing simple daily routines can provide a more practical approach than trying to overhaul everything at once. For ORGANA, the seasonal message is also a reminder that wellness isn't limited to a particular time of year. The habits that receive attention during summer can remain part of everyday routines throughout fall and into winter. "Summer makes people naturally think about hydration," Mills said. "When the weather cools down, it's easy to stop thinking about it. We want to remind people that hydration and minerals don't have an offseason." Consumers can explore and purchase ORGANA products through the company's Amazon storefront and on OneLavi.com. To learn more about the company's wellness philosophy visit organa.net. About ORGANA International Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness. FDA Disclaimer These statements have not been evaluated by the Food and Drug
- Sophos IRB, Inc.ALCMI and Sophos IRB Form Strategic Partnership to Advance Lung Cancer Clinical ResearchPartnership pairs ALCMI's international lung cancer research network with Sophos IRB's specialized oncology IRB expertise. — The Addario Lung Cancer Medical Institute (ALCMI), an international nonprofit specializing in investigator-initiated...
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLCTevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).
- The American Academy of OtolaryngologyFrom Gene Therapy to Whole-Body Health: Major ENT Research Coming to Los AngelesMore than 5,000 ear, nose and throat specialists from around the world will gather in Los Angeles next week for the American Academy of Otolaryngology–Head and Neck Surgery's 2026 Annual Meeting & OTO EXPO. The event will feature new research on...
- Enoumena Therapeutics Inc.Enoumena Therapeutics and AOP Health Announce Exclusive Canadian Commercialization Agreement for SIBBORAN(R) (landiolol)Enoumena Therapeutics Inc. and AOP Health today announced an exclusive commercialization agreement to expand Canadian institutional access to PrSIBBORAN® (landiolol hydrochloride), an ultra-short-acting, selective beta-1 adrenergic receptor blocker.Authorized by Health Canada in 2023, SIBBORAN is indicated for the short-term reduction of ventricular rate in patients with supraventricular tachycardia including atrial...
- Enoumena Therapeutics Inc.Enoumena Therapeutics et AOP Health annoncent une entente exclusive de commercialisation au Canada de SIBBORAN(R) (landiolol)Montréal, Québec et Vienne, Autriche--(8 octobre 2026) - Enoumena Therapeutics Inc. et AOP Health ont annoncé aujourd'hui la conclusion d'une entente exclusive de commercialisation visant à élargir l'accès des établissements de santé canadiens à PrSIBBORAN® (chlorhydrate de landiolol), un bêtabloquant sélectif des récepteurs bêta-1 adrénergiques à action ultra-courte.Autorisé par Santé Canada en 2023, SIBBORAN est indiqué pour la réduction à court terme de la fréquence...
- Psilera, Inc.Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use DisorderGovernment-backed research into next-generation psychedelics and neuroplastogens for addictive disorders underscores the continued momentum behind this promising drug class. — Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering...
- GOA Therapeutics Unveils New Data for GOA26, a First-in-Class Drug Candidate for Acute Alcohol Intoxication and PoisoningIn a porcine model of severe acute alcohol intoxication, GOA26 demonstrated a rapid reduction in blood alcohol concentration and multi-system biochemical recovery across metabolic, muscle, hematological and liver biomarkers.